Promising new cocktail for stomach cancer enters final trial phase
NCT ID NCT07315750
First seen Jan 06, 2026 · Last updated May 11, 2026 · Updated 20 times
Summary
This study tests a new three-drug combination (disitamab vedotin, trastuzumab, and tislelizumab) against standard chemotherapy plus trastuzumab with or without pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combo works better at slowing cancer growth and improving survival. About 555 adults who have not had prior treatment for advanced disease will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, BJ-Beijing, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.